Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Halozyme Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 82.4%. For fiscal 2025 it was 83.6%, against 84.3% the year before. The highest annual figure on record is 99.5% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.6% | −0.7 |
| FY2024 | Dec 31, 2024 | 84.3% | +7.5 |
| FY2023 | Dec 31, 2023 | 76.8% | −2.1 |
| FY2022 | Dec 31, 2022 | 78.9% | −2.7 |
| FY2021 | Dec 31, 2021 | 81.6% | −2.2 |
| FY2020 | Dec 31, 2020 | 83.8% | +7.0 |
| FY2019 | Dec 31, 2019 | 76.8% | −16.6 |
| FY2018 | Dec 31, 2018 | 93.3% | +3.2 |
| FY2017 | Dec 31, 2017 | 90.2% | +12.8 |
| FY2016 | Dec 31, 2016 | 77.4% | −1.0 |
| FY2015 | Dec 31, 2015 | 78.3% | +8.5 |
| FY2014 | Dec 31, 2014 | 69.8% | −18.8 |
| FY2013 | Dec 31, 2013 | 88.6% | −8.8 |
| FY2012 | Dec 31, 2012 | 97.4% | −2.1 |
| FY2011 | Dec 31, 2011 | 99.5% | +6.8 |
| FY2010 | Dec 31, 2010 | 92.8% | −5.0 |
| FY2009 | Dec 31, 2009 | 97.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 83.5% | −2.2 |
| Q1 FY2026 | Mar 31, 2026 | 79.0% | −2.8 |
| Q4 FY2025 | Dec 31, 2025 | 82.6% | −3.3 |
| Q3 FY2025 | Sep 30, 2025 | 84.4% | +1.4 |
| Q2 FY2025 | Jun 30, 2025 | 85.8% | +2.9 |
| Q1 FY2025 | Mar 31, 2025 | 81.7% | −3.8 |
| Q4 FY2024 | Dec 31, 2024 | 85.9% | +8.6 |
| Q3 FY2024 | Sep 30, 2024 | 83.0% | +8.3 |
| Q2 FY2024 | Jun 30, 2024 | 82.9% | +5.5 |
| Q1 FY2024 | Mar 31, 2024 | 85.5% | +7.2 |
| Q4 FY2023 | Dec 31, 2023 | 77.3% | +0.5 |
| Q3 FY2023 | Sep 30, 2023 | 74.6% | −2.7 |
| Q2 FY2023 | Jun 30, 2023 | 77.3% | −0.4 |
| Q1 FY2023 | Mar 31, 2023 | 78.3% | −8.1 |
| Q4 FY2022 | Dec 31, 2022 | 76.8% | −2.0 |
| Q3 FY2022 | Sep 30, 2022 | 77.4% | −6.6 |
| Q2 FY2022 | Jun 30, 2022 | 77.7% | −5.4 |
| Q1 FY2022 | Mar 31, 2022 | 86.4% | +6.9 |
| Q4 FY2021 | Dec 31, 2021 | 78.8% | +73.8 |
| Q3 FY2021 | Sep 30, 2021 | 84.0% | +78.6 |
| Q2 FY2021 | Jun 30, 2021 | 83.1% | +82.1 |
| Q1 FY2021 | Mar 31, 2021 | 79.5% | +70.2 |
| Q4 FY2020 | Dec 31, 2020 | 5.1% | −6.1 |
| Q3 FY2020 | Sep 30, 2020 | 5.3% | −9.5 |
| Q2 FY2020 | Jun 30, 2020 | 1.1% | −8.8 |
| Q1 FY2020 | Mar 31, 2020 | 9.3% | +2.7 |
| Q4 FY2019 | Dec 31, 2019 | 11.2% | +2.8 |
| Q3 FY2019 | Sep 30, 2019 | 14.9% | −7.2 |
| Q2 FY2019 | Jun 30, 2019 | 9.9% | −0.4 |
| Q1 FY2019 | Mar 31, 2019 | 6.6% | −5.6 |
| Q4 FY2018 | Dec 31, 2018 | 8.4% | +5.7 |
| Q3 FY2018 | Sep 30, 2018 | 22.1% | +13.8 |
| Q2 FY2018 | Jun 30, 2018 | 10.4% | −4.4 |
| Q1 FY2018 | Mar 31, 2018 | 12.1% | −1.0 |
| Q4 FY2017 | Dec 31, 2017 | 2.7% | −11.2 |
| Q3 FY2017 | Sep 30, 2017 | 8.2% | −4.9 |
| Q2 FY2017 | Jun 30, 2017 | 14.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 13.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 13.9% | – |
| Q3 FY2016 | Sep 30, 2016 | 13.2% | – |
See a number that looks wrong?